Evidence map›Paper›PMID 27901412›Full record

ArticleJournal of women's health (2002)2017

Oral Progestogens Versus Levonorgestrel-Releasing Intrauterine System for Treatment of Endometrial Intraepithelial Neoplasia<sup/>.

Mary L Marnach, Kristina A Butler, Michael R Henry, Catherine E Hutz, Carrie L Langstraat, Christine M Lohse, Petra M Casey

Registry-linked trialAbstract read
PubMed Publisher
In one paragraph

Article in Journal of women's health (2002), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07462663 (SHAPE-ENDO), which is not on this map. Cited by 9 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 4 pooled it
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07462663 phase4not yet recruitingstarted 2027, after this paper: background citation

SHAPE-ENDO (Strategic Hormonal Approach & Prehabilitation in Endometrial Cancer): An Open-Label, Pilot Randomized Clinical Trial Comparing Standard Immediate Surgery Versus a Multimodal Metabolic Optimization and Prehabilitation Strategy Before Surgery in Patients With Atypical Endometrial Hyperplasia or Low-Risk Endometrioid Endometrial Cancer and BMI ≥40 kg/m²

Ran2027Enrolled80Registered outcomes34Posted comparisons0ConditionsAtypical Endometrial Hyperplasia, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I, BMI>40, Endometrial CancerArmsDietetic-Nutritional intervention, Endometrial Biopsy With or Without Hysteroscopy, GLP-1 receptor agonist, Levonorgestrel IUD (Lng-IUD), Oral Progestins
PMID 33755728PMID 33667417PMID 36216945PMID 29266019PMID 17096437PMID 23021687PMID 25791635PMID 27654262PMID 30193337PMID 33397713PMID 34238643PMID 35314087other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 4 syntheses or guidelines pooled it, 18 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Endometrial hyperplasia as a risk factor of endometrial cancer.Archives of gynecology and obstetrics · 2022
    Pooled it
  4. ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.Virchows Archiv : an international journal of pathology · 2021
    Guideline
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mary L Marnach1 Department of Obstetrics and Gynecology, Mayo Clinic , Rochester, Minnesota.
Kristina A Butler2 Division of Pelvic Reconstructive Surgery, Mayo Clinic Hospital , Phoenix, Arizona.
Michael R Henry3 Division of Anatomic Pathology, Mayo Clinic , Rochester, Minnesota.
Catherine E Hutz1 Department of Obstetrics and Gynecology, Mayo Clinic , Rochester, Minnesota.
Carrie L Langstraat1 Department of Obstetrics and Gynecology, Mayo Clinic , Rochester, Minnesota.
Christine M Lohse5 Division of Biomedical Statistics and Informatics, Mayo Clinic , Rochester, Minnesota.
Petra M Casey1 Department of Obstetrics and Gynecology, Mayo Clinic , Rochester, Minnesota.
Mayo Clinic · USWinnMed · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLimited therapeutic guidelines exist regarding medical therapy, ideal dosing, duration of therapy, or recommendations for timing of endometrial reassessment for women with endometrial intraepithelial neoplasia (EIN) who desire fertility preservation or who are not optimal surgical candidates. We aimed to determine the effectiveness of oral progestogens (OP) versus the levonorgestrel-releasing intrauterine system (LNG IUS) in the medical treatment of EIN.

methodsWe retrospectively identified women with EIN at our institution from 2007 through 2014 and compared the outcomes of those treated with OP versus LNG IUS.

resultsAmong 390 women, 296 were initially treated with OP and 94 with LNG IUS. Baseline characteristics of the patient groups were comparable, except for higher median body mass index in the LNG IUS group versus the OP group (37 kg/m

conclusionsOP and LNG IUS offer similar endometrial protection for women with EIN. LNG IUS offers convenience, minimal adverse effects, reversibility, and long-term endometrial protection.

Indexed as

Intrauterine Devices, MedicatedAdministration, OralAdolescentAdultAgedAged, 80 and overContraceptive Agents, FemaleEndometrial HyperplasiaFemaleHumansLevonorgestrelMiddle AgedProgestinsProspective StudiesTime FactorsTreatment OutcomeContraceptive Agents, FemaleLevonorgestrelProgestinsendometrial adenocarcinomaendometrial hyperplasiaendometrial intraepithelial neoplasialevonorgestrel-releasing intrauterine systemoral progestogens

Identifiers

PMID27901412
OpenAlexW2558223455

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.